-
Abiraterone Acetate in Patient-Derived Spheroids
2026-09-11
Explore how Abiraterone acetate can be evaluated as a CYP17 inhibitor in patient-derived prostate cancer spheroids. This evidence-focused guide explains why model qualification, compound identity, and orthogonal readouts are essential when translating androgen biosynthesis research into meaningful drug-response data.
-
Bismuth Subsalicylate in Cell Assay Workflows
2026-09-10
This scenario-driven guide explains how Bismuth Subsalicylate, SKU A8382, can be incorporated into cell viability, proliferation, and apoptosis workflows without confusing formulation artifacts with biological effects. It covers compound compatibility, controls, storage, orthogonal readouts, and practical vendor-selection criteria.
-
Merbromin as a Dual-Use Fluorescent Probe
2026-09-10
Merbromin is more than a fluorescent dye: it is a protein–ligand interaction probe, enzyme inhibition assay reagent, and environmentally relevant mercury-containing compound. This guide connects spectroscopic assay design with protease screening, antimicrobial research, and evidence from MOF-based pollutant removal.
-
Caffeic Acid Phenethyl Ester: NF-κB Assay Logic
2026-09-09
Caffeic Acid Phenethyl Ester (CAPE) is more than an NF-κB inhibitor: it is a strategic perturbation tool for separating inflammatory pathway contributions from Fyn–Stat3 neurodegeneration phenotypes. This guide connects assay design, chemical handling, and cross-domain validation in angiogenesis and tumor-invasion models.
-
Primidone: TRPM3 and RIPK1 Research Workflows
2026-09-09
Primidone, also known as Mysoline, supports complementary TRPM3 channel and RIPK1 workflows spanning neurodevelopmental, neurodegenerative, and inflammatory disease research. This guide translates its concentration-dependent activity into practical assay setup, animal-model dosing, biomarker selection, and troubleshooting strategies.
-
Phebestin Reveals a Dual Aminopeptidase Targeting Strategy
2026-09-08
The reference study identifies phebestin, a bestatin-related aminopeptidase inhibitor, as a nanomolar antiplasmodial candidate active against both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. By combining stage-specific culture assays, washout experiments, molecular docking, and two mouse infection models, the authors connect broad parasite inhibition with putative PfM1AAP and PfM17LAP engagement while also defining important gaps for future validation.
-
TPPU: sEH Inhibitor Workflow for Bone & Inflammation
2026-09-08
TPPU is a nanomolar soluble epoxide hydrolase inhibitor for connecting fatty acid epoxide signaling with inflammatory pain, osteoclast biology, and redox assays. This practical guide covers formulation, concentration-response design, lipid-metabolite validation, troubleshooting, and translation limits.
-
NSP15 Inhibitors: Thymopentin and Oleuropein
2026-09-07
The 2021 reference study used structure-based virtual screening and molecular dynamics to identify thymopentin and oleuropein as high-ranking natural-product binders of the SARS-CoV-2 NSP15 endoribonuclease. Its results provide a computational starting point for antiviral validation, while also illustrating why docking and simulation findings must be separated from demonstrated biochemical inhibition.
-
Moesin as a Biomarker of Endothelial Injury in Sepsis
2026-09-07
Chen et al. identified circulating moesin as a severity-associated marker of endothelial injury in sepsis and linked it mechanistically to Rock1/myosin light chain and NF-κB signaling. The combination of patient samples, LPS and CLP mouse models, and HMEC experiments provides a useful framework for connecting biomarker behavior with vascular barrier dysfunction while also defining important limits on clinical interpretation.
-
Azilsartan Medoxomil: Meta-Analysis of Efficacy and Safety
2026-09-05
This systematic review and meta-analysis integrates randomized evidence on azilsartan medoxomil for hypertension, combining ambulatory and clinic blood-pressure outcomes with a structured safety assessment. Its dose-specific findings support further blood pressure regulation studies while indicating that the overall adverse-event profile is broadly comparable with control therapy, including in patients with diabetes.
-
Azilsartan Medoxomil: Meta-Analysis Findings
2026-09-04
This systematic review and meta-analysis integrates randomized evidence on azilsartan medoxomil for hypertension, combining ambulatory and clinic blood-pressure outcomes with a structured safety assessment. The findings indicate greater blood-pressure reduction at 40 and 80 mg than control therapy without a broad increase in adverse events, while the small diabetes subgroup supports cautious but relevant translational interpretation.
-
Propranolol Workflows for Translational Research
2026-09-04
Build reproducible Propranolol assays across cardiovascular, neural, and metabolic models with solvent-matched controls, exposure tracking, and decision-ready readouts. This workflow distinguishes direct β1AR/β2AR pharmacology from exploratory translational hypotheses, helping researchers troubleshoot dose, timing, and model-specific variability.
-
SP600125 JNK Inhibitor: Assay Workflow Guide
2026-09-03
Build more defensible JNK pathway experiments with SP600125 by connecting biochemical potency to cellular cytokine, phosphorylation, and apoptosis readouts. This guide translates a Chlamydia psittaci inflammation study into practical controls, dosing strategies, and troubleshooting steps for infection, inflammation, and cancer research.
-
Ciclesonide: From Lung Activation to ERAD Assay Design
2026-09-03
Ciclesonide combines lung-relevant prodrug activation with potent glucocorticoid receptor pharmacology. This article distinguishes validated respiratory applications from emerging ERAD concepts and provides an evidence-aware framework for designing translational assays.
-
Formononetin Protects Against Oxaliplatin Neurotoxicity
2026-09-02
The reference study identifies formononetin as an isoflavone that protects cultured sensory neurons from oxaliplatin-associated oxidative stress and apoptosis through Nrf2/HO-1 signaling. Its key translational insight is that neuroprotection can be separated from broad antioxidant activity: formononetin preserved oxaliplatin and paclitaxel anticancer effects in tumor-cell models, whereas N-acetylcysteine reduced them.